Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
2009 · Clinical Cancer Research · 218 citations
https://doi.org/10.1158/1078-0432.ccr-09-0062
D
David J. FitzGerald
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
101
Papers
7.3K
Citations
40
h-index
56
i10-index
David J. FitzGerald is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Toxin Mechanisms and Immunotoxins & Transgenic Plants and Applications & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 40, co-authored 86 publications.
Papers by this author
worksProteolytic Cleavage of a C-terminal Prosequence, Leading to Autoprocessing at the N Terminus, Activates Leucine Aminopeptidase from Pseudomonas aeruginosa
2009 · Journal of Biological Chemistry · 28 citations
https://doi.org/10.1074/jbc.m808686200
Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in persons with pancreatobiliary cancer or other mesothelin expressing solid tumors.
2021 · Journal of Clinical Oncology · 5 citations
https://doi.org/10.1200/jco.2021.39.3_suppl.tps452
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat